Risk factors for carbapenem-resistant Pseudomonas aeruginosa infection in a tertiary care hospital in Serbia

Journal of Infection in Developing Countries

Volumn 7, Issue 9, 2013, Pages 686-690

  Djordjevic, Zorana ^a   Folic, Marko ^b,c   Ruzic Zecevic, Dejana ^b,c   Ilic, Goran ^d   Jankovic, Slobodan ^b,c  

^a Clinical Center Kragujevac ^*  (Serbia)

^b Clinical Center   (Serbia)

^c UNIVERSITY OF KRAGUJEVAC   (Serbia)

^d Institute for Workers Health Protection 'Zastava'   (Serbia)

Author keywords

Carbapenem resistance; P. aeruginosa; Risk factors

Indexed keywords

AMIKACIN; CARBAPENEM; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ADULT; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; COHORT ANALYSIS; COMORBIDITY; FEMALE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LETTER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVENTION AND CONTROL; PROSPECTIVE STUDY; PSEUDOMONAS INFECTION; RISK FACTOR; SERBIA; TERTIARY HEALTH CARE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; COHORT STUDIES; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK FACTORS; SERBIA; TERTIARY CARE CENTERS;

EID: 84884271743     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.3516     Document Type: Letter

References (13)

1. Rossolini GM, Mantengoli E (2005) Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 11 (Suppl 4): 17-32.
2. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK, National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) NHSN annual update: Antimicrobialresistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 29: 996-1011.
3. Klevens RM, Edwards JR, Gaynes RP (2008) National Nosocomial Infections Surveillance System. The impact of antimicrobial-resistant, health care-associated infections on mortality in the United States. Clin Infect Dis 47: 927-930.
4. Deshpande LM, Fritsce TR, Jones RN (2004) Molecular epidemiology of selected multidrug-resistant bacteria: a global report of the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 49: 231-236.
5. Fortaleza CM, Freire MP, Filho Dde C, de Carvalho Ramos M (2006) Risk factors for recovery of imipenem- or ceftazidimeresistant Pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil. Infect Control Hosp Epidemiol 27: 901-906.
6. Onguru P, Erbay A, Bodur H, Baran G, Akinci E, Balaban N, Cevik MA (2008) Imipenem-Resistant Pseudomonas aeruginosa: Risk Factors for Nosocomial Infections. J Korean Med Sci 23: 982-987.
7. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y (2006) Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother; 50: 43-48.
8. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC (2002) Risk factors for imipenem-resistant Pseudomonas aeruginosa in hospitalized patients. Clin Infect Dis 34: 340-345.
9. Zavascki AP, Cruz RP, Goldani LZ (2005) Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients. J Hosp Infect 59: 96-101.
10. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO (2006) Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 27: 893-900.
11. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infections. Am J Infect Control 16: 128-140.
12. Kiska DL, Gilligan PH (1995) Pseudomonas and Burkholderia. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical microbiology. Washington, DC: American Society for Microbiology. 517-525.
13. National Committee for Clinical Laboratory Standards (2000) Performance standards for antimicrobial disk susceptibility tests. Approved standard. NCCLS document M2-A5. 6th ed. Wayne, PA: NCCCLS.